Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)

JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (, a developer of oral delivery systems, announced today that its Chief Executive Officer, Mr. Nadav Kidron, will be giving a company presentation at the 10th Annual Rodman & Renshaw Healthcare Conference at New York City's Palace Hotel on November 11. Mr. Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II Ballroom, located on the 4th floor of the hotel.

"The Rodman & Renshaw Conference will give Oramed an important platform to present the accomplishments we have achieved in our development of an oral insulin capsule and our unique position as a technology pioneer in the field of oral delivery solutions," said Kidron.

For more information about Rodman & Renshaw and the upcoming conference, please visit

For more information about Oramed Pharmaceuticals, please visit

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001


Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003


SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
6. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
8. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
9. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
10. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
11. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless ... , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic tools ...
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):